

# Alexander J F Lazar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5456451/publications.pdf>

Version: 2024-02-01

441  
papers

56,885  
citations

2311

98  
h-index

1589

216  
g-index

458  
all docs

458  
docs citations

458  
times ranked

57662  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	6.6	3,706
2	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
3	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	13.5	2,277
4	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	13.5	2,111
5	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018, 173, 291-304.e6.	13.5	1,718
6	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	13.5	1,670
7	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
8	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
9	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
10	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	7.7	1,158
11	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
12	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	3.3	1,023
13	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	5.1	921
14	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
15	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	7.7	750
16	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
17	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	689
18	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018, 23, 181-193.e7.	2.9	683

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	0.8	668
20	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017, 32, 204-220.e15.	7.7	642
21	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	13.5	620
22	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
23	<i>c</i> NRAS mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023.	2.0	589
24	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
25	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	7.7	478
26	Specific Mutations in the $\beta$ -Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors. <i>American Journal of Pathology</i> , 2008, 173, 1518-1527.	1.9	417
27	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	2.9	407
28	Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. <i>Modern Pathology</i> , 2012, 25, 1298-1306.	2.9	403
29	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	7.7	396
30	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	6.0	369
31	Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1772-1779.	0.8	351
32	Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 154-160.	0.3	334
33	Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma. <i>Science Translational Medicine</i> , 2011, 3, 98ra82.	5.8	328
34	Epithelioid Inflammatory Myofibroblastic Sarcoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 135-144.	2.1	309
35	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€³, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	5.1	288
36	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 370-374.	157.7	280

#	ARTICLE	IF	CITATIONS
37	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. <i>Human Pathology</i> , 2017, 67, 1-10.	1.1	275
38	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	13.5	272
39	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. <i>Nature Genetics</i> , 2014, 46, 376-379.	9.4	269
40	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017, 30, 1433-1442.	2.9	261
41	Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome. <i>Annals of Surgery</i> , 2009, 249, 1014-1022.	2.1	254
42	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	2.9	245
43	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	5.1	233
44	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 628-645.	7.7	231
45	MUC4 Is a Sensitive and Extremely Useful Marker for Sclerosing Epithelioid Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1444-1451.	2.1	230
46	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 7538-7546.	3.2	221
47	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
48	Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. <i>Human Pathology</i> , 2008, 39, 184-193.	1.1	214
49	Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. <i>Cancer</i> , 2011, 117, 4939-4947.	2.0	212
50	Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6500-6505.	3.3	210
51	Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). <i>Modern Pathology</i> , 2009, 22, 1201-1209.	2.9	198
52	Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. <i>Modern Pathology</i> , 2009, 22, 1446-1456.	2.9	196
53	Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 220-226.	1.2	195
54	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14333-14338.	3.3	194

#	ARTICLE	IF	CITATIONS
55	Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. <i>EMBO Reports</i> , 2007, 8, 497-503.	2.0	185
56	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF <sup>V600E</sup> Mutation. <i>Thyroid</i> , 2013, 23, 1277-1283.	2.4	184
57	Angiosarcoma. <i>Annals of Surgery</i> , 2010, 251, 1098-1106.	2.1	182
58	Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2079-2085.	1.9	178
59	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5537-5546.	3.2	169
60	The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. <i>Cancer Cell</i> , 2018, 33, 1128-1141.e7.	7.7	169
61	Genetic Alterations in Signaling Pathways in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 2301s-2307s.	3.2	168
62	Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. <i>American Journal of Clinical Pathology</i> , 2015, 143, 672-682.	0.4	168
63	A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. <i>Annals of Surgical Oncology</i> , 2009, 16, 910-919.	0.7	166
64	Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies. <i>PLoS ONE</i> , 2010, 5, e10105.	1.1	166
65	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. <i>Modern Pathology</i> , 2016, 29, 582-590.	2.9	164
66	Cutaneous Clear Cell Sarcoma: A Clinicopathologic, Immunohistochemical, and Molecular Analysis of 12 Cases Emphasizing its Distinction from Dermal Melanoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 216-222.	2.1	163
67	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	2.0	162
68	Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. <i>Modern Pathology</i> , 2010, 23, 567-573.	2.9	156
69	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. <i>Cancer Cell</i> , 2020, 37, 639-654.e6.	7.7	151
70	Human sebaceous tumors harbor inactivating mutations in LEF1. <i>Nature Medicine</i> , 2006, 12, 395-397.	15.2	149
71	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAF <sup>V600</sup> Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536.	3.2	145
72	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. <i>Journal of Pathology</i> , 2018, 244, 512-524.	2.1	144

#	ARTICLE	IF	CITATIONS
73	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	5.8	143
74	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunooncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
75	CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. <i>Cell</i> , 2013, 152, 1077-1090.	13.5	139
76	Sarcoma Epidemiology and Etiology: Potential Environmental and Genetic Factors. <i>Surgical Clinics of North America</i> , 2008, 88, 451-481.	0.5	138
77	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138
78	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021, 27, 141-151.	15.2	134
79	Primary Cutaneous Apocrine Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 682-690.	2.1	133
80	Ewing's Sarcoma: Standard and Experimental Treatment Options. <i>Current Treatment Options in Oncology</i> , 2009, 10, 126-140.	1.3	127
81	New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2739-2748.	0.7	126
82	Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. <i>Histopathology</i> , 2010, 56, 133-147.	1.6	125
83	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. <i>Journal of Thoracic Oncology</i> , 2022, 17, 200-213.	0.5	124
84	BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. <i>Modern Pathology</i> , 2015, 28, 575-586.	2.9	122
85	Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 474-480.	0.7	120
86	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
87	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	1.2	120
88	Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 148-157.	0.7	118
89	Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1650-1660.	1.9	116
90	Long-Term Outcomes in Patients with Radiation-Associated Angiosarcomas of the Breast Following Surgery and Radiotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1267-1274.	0.7	116

#	ARTICLE	IF	CITATIONS
91	Correlative Analyses of the SARCO28 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	3.2	115
92	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
93	Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 737-740.	4.3	111
94	Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. <i>Modern Pathology</i> , 2012, 25, 1378-1383.	2.9	111
95	Primary Vascular Tumors and Tumor-like Lesions of the Kidney: A Clinicopathologic Analysis of 25 Cases. <i>American Journal of Surgical Pathology</i> , 2010, 34, 942-949.	2.1	109
96	Staging Soft Tissue Sarcoma: Evolution and Change. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 282-291.	157.7	107
97	Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?. <i>Modern Pathology</i> , 2010, 23, 1301-1306.	2.9	107
98	Primitive Nonneural Granular Cell Tumors of Skin. <i>American Journal of Surgical Pathology</i> , 2005, 29, 927-934.	2.1	106
99	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	2.3	106
100	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
101	MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1 $\beta$ and Enhances $\beta$ -Catenin Signaling. <i>Cancer Research</i> , 2012, 72, 1751-1762.	0.4	104
102	Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. <i>Journal of Clinical Investigation</i> , 2011, 121, 174-183.	3.9	104
103	Site and Tumor Type Predicts DNA Mismatch Repair Status in Cutaneous Sebaceous Neoplasia. <i>American Journal of Surgical Pathology</i> , 2008, 32, 936-942.	2.1	103
104	NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. <i>Oncogene</i> , 2015, 34, 5069-5079.	2.6	102
105	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer's Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	1.3	99
106	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013, 8, e67306.	1.1	98
107	Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e30.	1.6	97
108	The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. <i>Clinical Sarcoma Research</i> , 2013, 3, 7.	2.3	96

#	ARTICLE	IF	CITATIONS
109	Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. <i>Annals of Surgical Oncology</i> , 2014, 21, 2136-2143.	0.7	96
110	Noncontact measurement of elasticity for the detection of soft-tissue tumors using phase-sensitive optical coherence tomography combined with a focused air-puff system. <i>Optics Letters</i> , 2012, 37, 5184.	1.7	95
111	Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 49-54.	0.7	94
112	Pleomorphic liposarcoma. <i>Cancer</i> , 2011, 117, 5359-5369.	2.0	92
113	Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 7314-7321.	3.2	90
114	Localized and metastatic myxoid/round cell liposarcoma. <i>Cancer</i> , 2013, 119, 1868-1877.	2.0	90
115	Nuclear $\beta$ -catenin localization and mutation of the CTNNB1 gene: a context-dependent association. <i>Modern Pathology</i> , 2018, 31, 1553-1559.	2.9	90
116	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
117	Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. <i>Journal of Neurosurgery</i> , 2017, 126, 319-329.	0.9	89
118	Cutaneous Digital Papillary Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1883-1891.	2.1	88
119	Clinical characteristics and outcomes with specific <i>BRAF</i> and <i>NRAS</i> mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 3821-3829.	2.0	87
120	Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3943-3955.	3.2	86
121	Molecular Diagnosis of Sarcomas: Chromosomal Translocations in Sarcomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1199-1207.	1.2	85
122	Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 6709-6715.	3.2	84
123	Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors. <i>Cancer Research</i> , 2011, 71, 185-196.	0.4	84
124	SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. <i>Clinical Cancer Research</i> , 2016, 22, 1150-1160.	3.2	84
125	Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1157-1168.	1.9	83
126	Title is missing!, 2017, , .		82



#	ARTICLE	IF	CITATIONS
127	Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. <i>Modern Pathology</i> , 2012, 25, 212-221.	2.9	81
128	ERG and FLI1 protein expression in epithelioid sarcoma. <i>Modern Pathology</i> , 2014, 27, 496-501.	2.9	81
129	USP6 activation in nodular fasciitis by promoter-swapping gene fusions. <i>Modern Pathology</i> , 2017, 30, 1577-1588.	2.9	79
130	Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). <i>Development (Cambridge)</i> , 2005, 132, 415-427.	1.2	77
131	ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. <i>Journal of Pathology</i> , 2012, 227, 223-233.	2.1	77
132	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , 2017, 31, 1109-1121.	2.7	75
133	Uterine Tumors With Neuroectodermal Differentiation. <i>American Journal of Surgical Pathology</i> , 2008, 32, 219-228.	2.1	74
134	Genetic aberrations of gastrointestinal stromal tumors. <i>Cancer</i> , 2008, 113, 1532-1543.	2.0	72
135	FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma. <i>Modern Pathology</i> , 2012, 25, 846-853.	2.9	72
136	An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. <i>Laboratory Investigation</i> , 2011, 91, 392-403.	1.7	71
137	Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. <i>PLoS ONE</i> , 2009, 4, e8075.	1.1	71
138	Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. <i>International Journal of Cancer</i> , 2008, 122, 711-718.	2.3	70
139	Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. <i>Modern Pathology</i> , 2009, 22, 66-70.	2.9	70
140	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2644-2651.	3.2	70
141	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
142	Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2145-2154.	0.7	69
143	EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. <i>Modern Pathology</i> , 2017, 30, 1312-1320.	2.9	69
144	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	1.1	69

#	ARTICLE	IF	CITATIONS
145	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4865-4873.	3.2	68
146	Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. <i>Histopathology</i> , 2015, 67, 699-708.	1.6	67
147	Myxofibrosarcoma. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 775-788.	0.6	67
148	Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. <i>Modern Pathology</i> , 2010, 23, 1307-1315.	2.9	66
149	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. <i>JAMA Network Open</i> , 2021, 4, e210945.	2.8	66
150	Liposarcoma in children and young adults: A multi-institutional experience. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1142-1146.	0.8	65
151	Outcome of Locally Recurrent and Metastatic Angiosarcoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 2502-2509.	0.7	64
152	Complete Soft Tissue Sarcoma Resection is a Viable Treatment Option for Select Elderly Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 2579-2586.	0.7	64
153	Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. <i>Cancer</i> , 2015, 121, 4088-4096.	2.0	64
154	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. <i>Modern Pathology</i> , 2015, 28, 587-595.	2.9	64
155	A Keratinocyte Hypermotility/Growth-Arrest Response Involving Laminin 5 and p16INK4A Activated in Wound Healing and Senescence. <i>American Journal of Pathology</i> , 2006, 168, 1821-1837.	1.9	63
156	Clinical responses to selumetinib (AZD6244;ARRY-42886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 799-805.	2.0	63
157	EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumorigenesis. <i>Journal of Pathology</i> , 2014, 232, 308-318.	2.1	62
158	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
159	New Strategies in Melanoma: Molecular Testing in Advanced Disease. <i>Clinical Cancer Research</i> , 2012, 18, 1195-1200.	3.2	61
160	Uterine Leiomyosarcoma Management, Outcome, and Associated Molecular Biomarkers: A Single Institution's Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2364-2372.	0.7	61
161	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017, 7, 11.	2.3	61
162	R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations. <i>American Journal of Pathology</i> , 2013, 182, 1494-1500.	1.9	60

#	ARTICLE	IF	CITATIONS
163	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 15-24.	1.1	59
164	Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis. <i>Annals of Surgical Oncology</i> , 2011, 18, 3762-3770.	0.7	58
165	Phase I Study of the Combination of Sorafenib and Temozolomide in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1120-1128.	3.2	57
166	Angiosarcoma. <i>American Journal of Dermatopathology</i> , 2013, 35, 432-437.	0.3	57
167	Dual Roles of RNF2 in Melanoma Progression. <i>Cancer Discovery</i> , 2015, 5, 1314-1327.	7.7	57
168	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. <i>Scientific Reports</i> , 2017, 7, 11836.	1.6	57
169	Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of Slug. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2405-2413.	2.5	56
170	Expression of ERG, an Ets family transcription factor, distinguishes cutaneous angiosarcoma from histological mimics. <i>Histopathology</i> , 2012, 61, 989-991.	1.6	56
171	A Preexisting Rare <i>PIK3CA</i> E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling. <i>Cancer Discovery</i> , 2018, 8, 556-567.	7.7	55
172	TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2010, 16, 2591-2604.	3.2	54
173	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2013, 109, 1085-1092.	2.9	54
174	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	13.7	54
175	Epithelioid Sarcoma and Unclassified Sarcoma with Epithelioid Features: Clinicopathological Variables, Molecular Markers, and a New Experimental Model. <i>Oncologist</i> , 2011, 16, 512-522.	1.9	53
176	Desmoid tumor: from surgical extirpation to molecular dissection. <i>Current Opinion in Oncology</i> , 2009, 21, 352-359.	1.1	52
177	High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 849-858.	1.5	51
178	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	51
179	Clinicopathologic Considerations: How Can We Fine Tune Our Approach to Sarcoma?. <i>Seminars in Oncology</i> , 2011, 38, S3-S18.	0.8	50
180	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmmunology</i> , 2017, 6, e1361097.	2.1	50

#	ARTICLE	IF	CITATIONS
181	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, 108, djw182.	3.0	49
182	Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clinical Sarcoma Research, 2012, 2, 2.	2.3	48
183	Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group (EORTC “Soft Tissue and Bone Sarcoma Group) Tj ETQq1 1 0.784314 rgBT / Overlock 10 emphasis on magnetic resonance imaging. European Journal of Cancer. 2016, 56, 37-44.	1.3	48
184	Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma. Clinical Cancer Research, 2012, 18, 4633-4645.	3.2	47
185	<i>TERT</i> promoter mutations in solitary fibrous tumour. Histopathology, 2018, 73, 843-851.	1.6	47
186	New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resistance Updates, 2011, 14, 52-66.	6.5	46
187	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. OncoImmunology, 2018, 7, e1385689.	2.1	46
188	Distinctive Dermal Clear Cell Mesenchymal Neoplasm: Clinicopathologic Analysis of Five Cases. American Journal of Dermatopathology, 2004, 26, 273-279.	0.3	45
189	New Therapeutic Targets in Soft Tissue Sarcoma. Advances in Anatomic Pathology, 2012, 19, 170-180.	2.4	45
190	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	2.1	45
191	Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Journal of Physical Education and Sports Management, 2018, 4, a002386.	0.5	45
192	Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma. Modern Pathology, 2008, 21, 1303-1310.	2.9	44
193	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.6	44
194	Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors. Clinical Cancer Research, 2012, 18, 2545-2557.	3.2	44
195	p53 Staining Correlates With Tumor Type and Location in Sebaceous Neoplasms. American Journal of Dermatopathology, 2012, 34, 129-138.	0.3	44
196	Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. Journal of Cutaneous Pathology, 2012, 39, 493-499.	0.7	44
197	Mesenchymal to epithelial transition in sarcomas. European Journal of Cancer, 2014, 50, 593-601.	1.3	44
198	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	1.1	43

#	ARTICLE	IF	CITATIONS
199	PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms. American Journal of Surgical Pathology, 2016, 40, 1305-1315.	2.1	43
200	The genomic landscape of epithelioid sarcoma cell lines and tumours. Journal of Pathology, 2016, 238, 63-73.	2.1	43
201	Pathology of Gastrointestinal Stromal Tumors. Clinical Medicine Insights Pathology, 2012, 5, CPath.S9689.	0.6	42
202	Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors. Molecular Cancer Therapeutics, 2012, 11, 1758-1769.	1.9	41
203	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	3.4	41
204	CTNNB1 Genotyping and APC Screening in Pediatric Desmoid Tumors: A Proposed Algorithm. Pediatric and Developmental Pathology, 2012, 15, 361-367.	0.5	40
205	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surgery, 2016, 151, 347.	2.2	40
206	Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate. Clinical Cancer Research, 2007, 13, 6727-6734.	3.2	39
207	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer, 2007, 109, 2323-2333.	2.0	39
208	Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunology, Immunotherapy, 2012, 61, 1113-1124.	2.0	39
209	Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases. Clinical Sarcoma Research, 2015, 5, 7.	2.3	39
210	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	2.9	39
211	Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma. Clinical Cancer Research, 2011, 17, 5901-5912.	3.2	38
212	Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance. Cancer Research, 2012, 72, 4724-4732.	0.4	38
213	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle, 2015, 14, 2323-2332.	1.3	38
214	Metastasizing Adenocarcinoma and Multiple Neoplastic Proliferations Arising in a Nevus Sebaceus. American Journal of Dermatopathology, 2007, 29, 462-466.	0.3	37
215	Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth <i>in vitro</i> and <i>in vivo</i> . Clinical Cancer Research, 2008, 14, 2785-2795.	3.2	37
216	Metastatic basal cell carcinoma exhibits reduced actin expression. Modern Pathology, 2008, 21, 540-543.	2.9	36

#	ARTICLE	IF	CITATIONS
217	“Difficult to diagnose”™ desmoid tumours: a potential role for <i>CTNNB1</i> mutational analysis. <i>Histopathology</i> , 2011, 59, 336-340.	1.6	36
218	Clinicopathological features and clinical outcomes associated with <i>TP53</i> and <i>BRAF</i> <sup>N</sup> onâ€ <sup>V</sup> mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	2.0	36
219	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021, 148, 1040-1050.	2.3	36
220	Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. <i>Cancer</i> , 2011, 117, 380-389.	2.0	35
221	<i>lkk4a/Arf</i> Inactivation with Activation of the NF-Î®B/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma. <i>Cancer Research</i> , 2012, 72, 4682-4695.	0.4	35
222	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 195-206.	1.3	35
223	Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin*. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 245-250.	0.7	34
224	Contemporary Pathology of Gastrointestinal Stromal Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 49-68.	0.9	34
225	Sarcoma metastases to the skin. <i>Cancer</i> , 2012, 118, 2900-2904.	2.0	34
226	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2015, 144, 713-721.	0.4	34
227	Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. <i>Modern Pathology</i> , 2008, 21, 1121-1129.	2.9	33
228	Midkine Enhances Soft-Tissue Sarcoma Growth: A Possible Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2008, 14, 5033-5042.	3.2	33
229	Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2014, 21, 2499-2505.	0.7	33
230	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2102.	2.2	33
231	Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. <i>Acta Biomaterialia</i> , 2019, 100, 38-51.	4.1	33
232	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , 2021, 34, 108678.	2.9	33
233	IFN Regulatory Factor 8 Sensitizes Soft Tissue Sarcoma Cells to Death Receptorâ€“Initiated Apoptosis via Repression of FLICE-like Protein Expression. <i>Cancer Research</i> , 2009, 69, 1080-1088.	0.4	32
234	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencingâ€“Based Oncology Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 463-471.	1.2	32

#	ARTICLE	IF	CITATIONS
235	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021, 148, 560-571.	2.3	32
236	Combined Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor Blockade with Chemotherapy for Treatment of Local, Uterine, and Metastatic Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 5466-5475.	3.2	31
237	Desmoid Tumor. <i>Annals of Plastic Surgery</i> , 2011, 67, 551-564.	0.5	31
238	Three-dimensional computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas. <i>Journal of Biomedical Optics</i> , 2013, 19, 021102.	1.4	31
239	Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. <i>Molecular Cancer</i> , 2015, 14, 55.	7.9	31
240	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
241	Epidermodysplasia verruciformis in the setting of graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, S78-S80.	0.6	30
242	Nevoid Melanoma. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 243-253.	0.7	30
243	Comparison of Laboratory-Developed Tests and FDA-Approved Assays for <i>BRAF</i> , <i>EGFR</i> , and <i>KRAS</i> Testing. <i>JAMA Oncology</i> , 2018, 4, 838.	3.4	30
244	Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. <i>Histopathology</i> , 2009, 55, 750-755.	1.6	29
245	Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. <i>Histopathology</i> , 2015, 66, 627-638.	1.6	29
246	Modeling synovial sarcoma metastasis in the mouse: PI3K <sup>2</sup> -lipid signaling and inflammation. <i>Journal of Experimental Medicine</i> , 2016, 213, 2989-3005.	4.2	29
247	Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 2965-2978.	3.9	29
248	Renal cell carcinoma marker (RCC-Ma) is specific for cutaneous metastasis of renal cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 381-385.	0.7	28
249	Neoadjuvant treatment of soft tissue sarcoma: A multimodality approach. <i>Journal of Surgical Oncology</i> , 2010, 101, 327-333.	0.8	28
250	Dermatofibrosarcoma Protuberans With Unusual Sarcomatous Transformation: A Series of 4 Cases With Molecular Confirmation. <i>American Journal of Dermatopathology</i> , 2011, 33, 354-360.	0.3	28
251	Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. <i>Oncogene</i> , 2017, 36, 5421-5431.	2.6	28
252	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. <i>Oncotarget</i> , 2018, 9, 19891-19899.	0.8	28

#	ARTICLE	IF	CITATIONS
253	Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. <i>Cancer</i> , 2009, 115, 2971-2979.	2.0	27
254	Synovial Sarcoma of the Head and Neck: A Single Institution Review. <i>Sarcoma</i> , 2017, 2017, 1-8.	0.7	27
255	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018, 20, 37.	1.8	27
256	T-cell-rich angiomatoid polypoid pseudolymphoma of the skin: a clinicopathologic study of 17 cases and a proposed nomenclature. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 475-482.	0.7	26
257	Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1167-1174.	0.4	26
258	FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. <i>Histology and Histopathology</i> , 2012, 27, 641-9.	0.5	26
259	RNA Interference of PARG Could Inhibit the Metastatic Potency of Colon Carcinoma Cells via PI3-Kinase/Akt Pathway. <i>Cellular Physiology and Biochemistry</i> , 2012, 29, 361-372.	1.1	24
260	Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2220-2228.	0.7	24
261	A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1679-1685.	1.2	24
262	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24
263	B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	3.2	24
264	Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity. <i>Journal of Cutaneous Pathology</i> , 2008, 35, 647-650.	0.7	23
265	The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. <i>Histopathology</i> , 2011, 59, 556-561.	1.6	23
266	PAX3/FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 213-220.	1.2	23
267	NF1+/Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. <i>Cancer Research</i> , 2017, 77, 4486-4497.	0.4	23
268	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
269	Merkel Cell Tumor in a Trichilemmal Cyst: Collision or Association?. <i>American Journal of Dermatopathology</i> , 2007, 29, 180-183.	0.3	22
270	The Skin Allograft Revisited: A Potentially Permanent Wound Coverage Option in the Critically Ill Patient. <i>Plastic and Reconstructive Surgery</i> , 2009, 123, 1755-1758.	0.7	22



#	ARTICLE	IF	CITATIONS
271	Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 231-238.	0.7	22
272	Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. <i>Clinical Sarcoma Research</i> , 2012, 2, 25.	2.3	22
273	<i>BRAF</i> , <i>NRAS</i> and <i>KIT</i> sequencing analysis of spindle cell melanoma. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 821-825.	0.7	22
274	AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. <i>BMC Cancer</i> , 2015, 15, 901.	1.1	22
275	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 563-580.	0.7	22
276	Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. <i>Cancer Cytopathology</i> , 2021, 129, 374-382.	1.4	22
277	Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 941-944.	2.1	21
278	Telomerase Suppresses Formation of ALT-Associated Single-Stranded Telomeric C-Circles. <i>Molecular Cancer Research</i> , 2013, 11, 557-567.	1.5	21
279	Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors: A Series of 5 Cases With Molecular Analysis Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors : A Series of 5 Cases with Molecular Analysis.. <i>American Journal of Dermatopathology</i> , 2009, 31, 297-300.	0.3	20
280	Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. <i>Journal of Pathology</i> , 2011, 225, 574-582.	2.1	20
281	New, Tolerable $\beta$ -Secretase Inhibitor Takes Desmoid Down a Notch. <i>Clinical Cancer Research</i> , 2015, 21, 7-9.	3.2	20
282	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	1.9	20
283	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019, 11, 677.	1.7	20
284	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
285	Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	20
286	Nephrogenic fibrosing dermopathy with recurrence after allograft failure. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, S109-S111.	0.6	19
287	Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. <i>Molecular Oncology</i> , 2008, 2, 161-163.	2.1	19
288	Line-scan Raman microscopy complements optical coherence tomography for tumor boundary detection. <i>Laser Physics Letters</i> , 2014, 11, 105602.	0.6	19

#	ARTICLE	IF	CITATIONS
289	Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. <i>BMC Cancer</i> , 2015, 15, 886.	1.1	19
290	Cutaneous nodular fasciitis with genetic analysis: a case series. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1143-1149.	0.7	19
291	Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 816-826.	1.5	19
292	Clinicopathological analysis of <i>ATRX</i> , <i>DAXX</i> and <i>NOTCH</i> receptor expression in angiosarcomas. <i>Histopathology</i> , 2018, 72, 239-247.	1.6	19
293	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	1.5	19
294	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	2.9	19
295	Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. <i>Annals of Oncology</i> , 2010, 21, 1112-1120.	0.6	18
296	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 989-1008.	1.2	18
297	Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. <i>Human Pathology</i> , 2015, 46, 1015-1026.	1.1	18
298	Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. <i>Cancer</i> , 2020, 126, 3265-3273.	2.0	18
299	Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation <sup>+</sup> . <i>Histopathology</i> , 2021, 78, 321-326.	1.6	18
300	Tumors of the surface epithelium. , 2012, , 1076-1149.		18
301	Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. <i>Human Pathology</i> , 2022, 121, 73-80.	1.1	18
302	Sarcoma molecular testing: Diagnosis and prognosis. <i>Current Oncology Reports</i> , 2007, 9, 309-315.	1.8	17
303	The molecular pathology of sarcomas. <i>Cancer Biomarkers</i> , 2011, 9, 475-491.	0.8	17
304	Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. <i>Cancer</i> , 2015, 121, 3659-3667.	2.0	17
305	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. <i>Laboratory Investigation</i> , 2016, 96, 885-894.	1.7	17
306	MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. <i>British Journal of Radiology</i> , 2016, 89, 20150308.	1.0	17

#	ARTICLE	IF	CITATIONS
307	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. <i>Cell Reports</i> , 2021, 36, 109410.	2.9	17
308	Revealing retroperitoneal liposarcoma morphology using optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2011, 16, 020502.	1.4	16
309	Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. <i>Stem Cell Research</i> , 2013, 11, 772-781.	0.3	16
310	The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1297-1310.	1.2	16
311	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 189-207.e11.	0.6	16
312	The Long Noncoding RNA <i>NEAT1</i> Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. <i>Molecular Cancer Research</i> , 2020, 18, 1534-1544.	1.5	16
313	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1597-1605.	2.1	16
314	Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. <i>Oncotarget</i> , 2014, 5, 9065-9078.	0.8	16
315	Cellular blue nevi of the eyelid: A possible diagnostic pitfall. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 257-260.	0.6	15
316	Non-Radiographic Risk Factors Differentiating Atypical Lipomatous Tumors from Lipomas. <i>Frontiers in Oncology</i> , 2016, 6, 197.	1.3	15
317	Sarcoma Brain Metastases: 28 Years of Experience at a Single Institution. <i>Annals of Surgical Oncology</i> , 2016, 23, 962-967.	0.7	15
318	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. <i>Scientific Reports</i> , 2016, 6, 19649.	1.6	15
319	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	1.9	15
320	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	5.8	15
321	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. <i>Cancer</i> , 2021, 127, 2666-2673.	2.0	15
322	The clear cell sarcoma functional genomic landscape. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
323	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.3	14
324	Increased Vascular Endothelial Growth Factor-C Expression Is Insufficient to Induce Lymphatic Metastasis in Human Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2009, 15, 2637-2646.	3.2	14

#	ARTICLE	IF	CITATIONS
325	COL1A1:PDGFB Chimeric Transcripts Are Not Present in Indeterminate Fibrohistiocytic Lesions of the Skin. <i>American Journal of Dermatopathology</i> , 2010, 32, 149-153.	0.3	14
326	Pleomorphic fibroma and dermal atypical lipomatous tumor: are they related?. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 379-384.	0.7	14
327	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021, 11, 9362.	1.6	14
328	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	14
329	Targeted therapies for sarcomas: new roles for the pathologist. <i>Histopathology</i> , 2014, 64, 119-133.	1.6	13
330	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	1.9	13
331	The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. <i>Laboratory Investigation</i> , 2015, 95, 951-961.	1.7	12
332	Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. <i>Journal of Neuro-Oncology</i> , 2016, 127, 155-163.	1.4	12
333	Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. <i>Journal of Neurosurgery</i> , 2018, 129, 805-814.	0.9	12
334	Primary chondroosseous melanoma (chondrosarcomatous and osteosarcomatous melanoma). <i>Journal of Cutaneous Pathology</i> , 2018, 45, 146-150.	0.7	12
335	Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 484-489.	0.7	12
336	Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1203-1211.	1.2	12
337	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. <i>Acta Neuropathologica</i> , 2021, 142, 565-590.	3.9	12
338	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177.	0.4	12
339	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 903-913.	1.9	12
340	Introducing New College of American Pathologists Reporting Templates for Cancer Biomarkers. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 157-158.	1.2	11
341	Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	0.7	11
342	Prognosis of T1 synovial sarcoma depends upon surgery by oncologic surgeons. <i>Journal of Surgical Oncology</i> , 2016, 114, 490-494.	0.8	11

#	ARTICLE	IF	CITATIONS
343	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. <i>Translational Oncology</i> , 2017, 10, 546-554.	1.7	11
344	Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. <i>Gynecologic Oncology</i> , 2018, 151, 243-249.	0.6	11
345	Role of Elevated <i>PHIP</i> Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4119-4125.	3.2	11
346	Extraskeletal Myxoid Chondrosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 744-748.	0.6	11
347	T-cell trafficking plays an essential role in tumor immunity. <i>Laboratory Investigation</i> , 2019, 99, 85-92.	1.7	11
348	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
349	The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. <i>Molecular Cell</i> , 2022, 82, 1737-1750.e8.	4.5	11
350	Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 730-733.	0.7	10
351	Undifferentiated "round-cell" ("Ewing-like") sarcoma: not always so-round nor Ewing-like. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 371-372.	1.4	10
352	PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation. <i>Modern Pathology</i> , 2019, 32, 154-156.	2.9	10
353	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021, 11, 631766.	1.3	10
354	Expression and clinical correlations of PRAME in sarcoma subtypes. <i>Journal of Clinical Oncology</i> , 2016, 34, 11067-11067.	0.8	10
355	Expression of "drugable" tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. <i>Histopathology</i> , 2011, 59, 156-159.	1.6	9
356	Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma. <i>BMC Clinical Pathology</i> , 2014, 14, 42.	1.8	9
357	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 355-357.	1.2	9
358	Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. <i>Cancer Biology and Therapy</i> , 2016, 17, 129-138.	1.5	9
359	Molecular profiling of sarcomas: new vistas for precision medicine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 243-255.	1.4	9
360	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	1.9	9

#	ARTICLE	IF	CITATIONS
361	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	5.8	9
362	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	2.0	9
363	The role of phosphorylated signal transducer and activator of transcription 3 (<scp>pSTAT</scp>3) in peripheral nerve sheath tumours. <i>Histopathology</i> , 2017, 70, 946-953.	1.6	8
364	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 728-731.	0.3	8
365	Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. <i>Npj Genomic Medicine</i> , 2021, 6, 30.	1.7	8
366	Title is missing!. , 2017, , .		8
367	Title is missing!. , 2017, , .		8
368	Connective tissue tumors. , 2012, , 1588-1768.		8
369	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. <i>International Journal of Cancer</i> , 2022, 150, 2012-2024.	2.3	8
370	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in<i>CTNNB1</i>or<i>APC</i>: A Multi-institutional Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 4092-4104.	3.2	8
371	Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. <i>Melanoma Research</i> , 2017, 27, 126-133.	0.6	7
372	Identification of preoperative factors associated with outcomes following surgical management of intraâ€abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. <i>Journal of Surgical Oncology</i> , 2018, 117, 879-885.	0.8	7
373	The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1799-1805.	0.8	7
374	Identification of MicroRNAâ€™mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. <i>Cancers</i> , 2021, 13, 5301.	1.7	7
375	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	2.1	7
376	Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. <i>Laboratory Investigation</i> , 2022, 102, 658-666.	1.7	7
377	Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. <i>Npj Precision Oncology</i> , 2022, 6, 21.	2.3	7
378	Impact of Surgical Resection for Subdiaphragmatic Paragangliomas. <i>World Journal of Surgery</i> , 2014, 38, 733-741.	0.8	6

#	ARTICLE	IF	CITATIONS
379	Extraskelatal Osteosarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 238-242.	0.6	6
380	INSM1 Expression in Angiosarcoma. American Journal of Clinical Pathology, 2021, 155, 575-580.	0.4	6
381	Tumors of the sweat glands. , 2012, , 1508-1570.		6
382	Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. Journal of Cutaneous Pathology, 2017, 44, 692-697.	0.7	5
383	The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. Journal of Surgical Oncology, 2019, 120, 382-388.	0.8	5
384	A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. Journal of Pathology, 2021, 254, 109-120.	2.1	5
385	Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. Journal of Cutaneous Pathology, 2022, 49, 231-245.	0.7	5
386	Title is missing!. , 2017, , .		5
387	L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases. Laboratory Investigation, 0, , .	1.7	5
388	Differential Expression of Cysteine Dioxygenase 1 in Complex Karyotype Liposarcomas. Biomarkers in Cancer, 2014, 6, BIC.S14683.	3.6	4
389	Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. American Journal of Surgical Pathology, 2015, 39, 1701-1707.	2.1	4
390	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 787-792.	2.3	4
391	Toward an effective use of $\beta$ -catenin immunohistochemistry in the evaluation of challenging melanocytic lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 535-537.	1.4	4
392	The immune microenvironment of uterine adenosarcomas. Clinical Sarcoma Research, 2020, 10, 5.	2.3	4
393	Title is missing!. , 2017, , .		4
394	Clinical characteristics of patients with non-V600 BRAF mutant melanomas.. Journal of Clinical Oncology, 2014, 32, 9100-9100.	0.8	4
395	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget, 2022, 13, 521-533.	0.8	4
396	Nevoid Melanoma. Surgical Pathology Clinics, 2009, 2, 521-533.	0.7	3

#	ARTICLE	IF	CITATIONS
397	Analysis of $\alpha$ v integrin protein expression in human eyelid and periorbital squamous cell carcinomas. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 570-575.	0.7	3
398	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1271-1275.	1.2	3
399	The PI3K-AKT Pathway in Melanoma. , 2016, , 165-180.		3
400	Title is missing!. , 2017, , .		3
401	Tumors of the hair follicle. , 2012, , 1445-1487.		3
402	Overview of the TREC 2017 Precision Medicine Track. , 2017, 26, .		3
403	Overview of the TREC 2019 Precision Medicine Track. , 2019, 1250, .		3
404	Pseudocystic dermatofibrosarcoma protuberans: report of two cases and demonstration of COL1A1 $\rightarrow$ PDGFB rearrangement. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 356-360.	0.7	2
405	Computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas. <i>Proceedings of SPIE</i> , 2013, , .	0.8	2
406	Synovial Sarcoma of the Hand and Foot. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 361-368.	0.6	2
407	Analytical protocol to identify local ancestry-associated molecular features in cancer. <i>STAR Protocols</i> , 2021, 2, 100766.	0.5	2
408	Synovial sarcoma: Evaluation of response to treatment with gemcitabine and docetaxel. <i>Journal of Clinical Oncology</i> , 2014, 32, 10564-10564.	0.8	2
409	NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities. <i>Pathology and Oncology Research</i> , 2022, 28, 1610237.	0.9	2
410	Clonality, Mutation and Kaposi Sarcoma: A Systematic Review. <i>Cancers</i> , 2022, 14, 1201.	1.7	2
411	Pigmented <i>PRRX1::NCOA1</i> rearranged fibroblastic tumor: A rare morphologic variant of an emerging mesenchymal tumor. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 802-807.	0.7	2
412	Raman spectroscopy complements optical coherent tomography in tissue classification and cancer detection. , 2015, , .		1
413	Challenges in next generation sequencing analysis of somatic mutations in transplant patients. <i>Cancer Genetics</i> , 2018, 226-227, 17-22.	0.2	1
414	Orthopedic Oncologic Surgical Specimen Management and Surgical Pathology. , 2013, , 43-74.		1



#	ARTICLE	IF	CITATIONS
415	Title is missing!. , 2017, , .		1
416	Abstract 3875: SSX drives gain-of-function BAF complex chromatin affinity and genomic targeting in synovial sarcoma. Cancer Research, 2017, 77, 3875-3875.	0.4	1
417	Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.. Journal of Clinical Oncology, 2014, 32, 10512-10512.	0.8	1
418	A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma.. Journal of Clinical Oncology, 2015, 33, 9071-9071.	0.8	1
419	Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response.. Journal of Clinical Oncology, 2015, 33, e20051-e20051.	0.8	1
420	SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone. American Journal of Clinical Pathology, 2022, , .	0.4	1
421	Combining a focused air-puff system with phase-sensitive optical coherence tomography for the detection of soft-tissue tumors based on elasticity measurement. , 2013, , .		0
422	Prognostic gene expression signatures in sarcoma: finding clarity in complexity. Annals of Oncology, 2018, 29, 1632-1633.	0.6	0
423	Applications of Molecular Testing to Differential Diagnosis. , 2019, , 513-556.		0
424	Tumors of neuroectodermal origin. , 2020, , 437-538.		0
425	Skeletal Muscle Tumors. , 2020, , 283-296.		0
426	Soft Tissue. , 2020, , 229-283.		0
427	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Archives of Pathology and Laboratory Medicine, 2021, 145, 842-850.	1.2	0
428	Pathology of Desmoid Tumors. , 2012, , 17-28.		0
429	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutationâ€“positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	0.8	0
430	Phase I study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomas.. Journal of Clinical Oncology, 2014, 32, 10571-10571.	0.8	0
431	Application of Molecular Pathology to Cutaneous Melanocytic Lesions. Molecular Pathology Library, 2015, , 103-124.	0.1	0
432	Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS).. Journal of Clinical Oncology, 2015, 33, 9064-9064.	0.8	0

#	ARTICLE	IF	CITATIONS
433	Clinical Characteristics and Treatment Outcomes of Clear Cell Chondrosarcomas: MD Anderson Cancer Center Series.. Journal of Clinical Oncology, 2015, 33, 10531-10531.	0.8	0
434	A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets.. Journal of Clinical Oncology, 2015, 33, 9039-9039.	0.8	0
435	Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts).. Journal of Clinical Oncology, 2015, 33, 9057-9057.	0.8	0
436	Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations.. Journal of Clinical Oncology, 2015, 33, 10550-10550.	0.8	0
437	Head and neck synovial sarcomas: Clinical characteristics and survival.. Journal of Clinical Oncology, 2016, 34, e22523-e22523.	0.8	0
438	Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (mut).. Journal of Clinical Oncology, 2016, 34, 9535-9535.	0.8	0
439	Title is missing!. , 2017, , .		0
440	Genomic Applications in Melanoma. , 2019, , 509-540.		0
441	AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, 511-525.	0.2	0